Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | MMP8 | P22894 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4127273 | 1.00 | PIN1 (0.42) | PIN1MEN1KMT2ANPC1POLB | |
| SCHEMBL4006311 | 0.92 | PIN1 (0.40) | PIN1MEN1KMT2ANPC1POLB | |
| SCHEMBL4000449 | 0.90 | PIN1 (0.43) | PIN1MEN1KMT2ANPC1POLB | |
| SCHEMBL4007055 | 0.87 | KIF11 (0.42) | PIN1MEN1KMT2ANPC1POLB | |
| SCHEMBL3997359 | 0.86 | MAPT (0.38) | MEN1KMT2ANPC1POLBTDP1 | |
| SCHEMBL4004995 | 0.86 | MAPT (0.38) | MEN1KMT2ANPC1POLBTDP1 | |
| SCHEMBL3999030 | 0.86 | PIN1 (0.40) | PIN1MEN1KMT2ANPC1POLB | |
| SCHEMBL4000607 | 0.86 | PIN1 (0.40) | PIN1MEN1KMT2ANPC1POLB | |
| SCHEMBL3999925 | 0.86 | PIN1 (0.40) | PIN1MEN1KMT2ANPC1POLB | |
| SCHEMBL14034601 | 0.85 | PIN1 (0.38) | PIN1MEN1KMT2ANPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538105-B2 | Anti-infective agents | ABBOTT LABORATORIES (US) | 2009-05-26 | — | — | US | disclosed |
| WO-2008144500-A2 | 1-METHYL-BENZO[1,2,4]THIADIAZINE, 1-OXIDE DERIVATIVES | ANADYS PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080292588-A1 | 1-METHYL-BENZO[1,2,4]THIADIAZINE 1-OXIDE DERIVATIVES | ANADYS PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080193413-A1 | Anti-Infective Agents | ABBOTT LABORATORIES (US) | 2008-08-14 | — | — | US | disclosed |
| US-7378414-B2 | Viricides for infections caused by an RNA-containing virus; enzyme inhibitors for a hepatitis C virus (HCV) polymerase; inhibiting HCV viral replication; liver cirrhosis; e. g., 3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-1,1-dipropyl-2(1H)-naphthalenone | ABBOTT LABORATORIES (US) | 2008-05-27 | — | — | US | disclosed |
| US-20050107364-A1 | Viricides for infections caused by an RNA-containing virus; enzyme inhibitors for a hepatitis C virus (HCV) polymerase; inhibiting HCV viral replication; liver cirrhosis; e. g., 3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-1,1-dipropyl-2(1H)-naphthalenone | ABBVIE INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005019191-A2 | 1, 1-DIOXIDO-4H-1,2,4-BENZOTHIADIAZINE DERIVATE UND VERWANDTE VERBINDUNGEN ALS INHIBITOREN DER HCV POLYMERASE ZUR BEHANDLUNG VON HEPATITIS C | ABBOTT LABORATORIES (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080292588-A1 | 1-METHYL-BENZO[1,2,4]THIADIAZINE 1-OXIDE DERIVATIVES | CYP1B1, CYP2E1, DAZAP1 | PIN1 3127/4885MEN1 3139/4885KMT2A 1229/4885 |
| US-20080193413-A1 | Anti-Infective Agents | POLI, RPL5, POLRMT | PIN1 2340/4885MEN1 4787/4885KMT2A 4638/4885 |
| US-20050107364-A1 | Viricides for infections caused by an RNA-containing virus; enzyme inhibitors for a hepatitis C virus (HCV) polymerase; inhibiting HCV viral replication; liver cirrhosis; e. g., 3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-1,1-dipropyl-2(1H)-naphthalenone | POLRMT, RNASE1, RNGTT | PIN1 1970/4885MEN1 4794/4885KMT2A 3557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.